COMUNICADO: El Journal of the American Medical Association publica el estudio RIO-North America (y 3)

Europa Press Economía Finanzas
Actualizado: miércoles, 15 febrero 2006 14:31
Seguir en

    
    Contactos de medios:  Nazira Amra, +33-1-53-77-47-88,
                          nazira.amra@sanofi-aventis.com
                          Julissa Viana, +1-908-243-1232,
                          julissa.viana@sanofi-aventis.com
    Referencias:
    (1) Sharma A. M. Adipose tissue: a mediator of cardiovascular risk. Int J
        Obes Relat Metab Disord. 2002; 26 Suppl 4: S5-S7
    (2) Van Gaal L.F., Rissanen A.M, Sheen A.J., Ziegler O., Rossner S., for
        the RIO-Europe study group. Effects of the cannabinoid-1 receptor
        blocker rimonabant on weight reduction and cardiovascular risk
        factors in overweight patients: 1-year experience from the RIO-Europe
        study. Lancet 2005; 365:1389-97.
    (3) Despres J-P., Golay A., Sjostrom L., for the RIO-Europe study group.
        Effects of rimonabant on metabolic risk factors in overweight
        patients with dyslipidemia. New Engl J Med 2005; 353:2121-34.

Página web: http://www.sanofi-aventis.com

Contacto: Nazira Amra, +33-1-53-77-47-88, nazira.amra@sanofi-aventis.com, Julissa Viana, +1-908-243-1232, julissa.viana@sanofi-aventis.com, ambos de sanofi-aventis; Company News On-Call: http://www.prnewswire.com/comp/232375.html

Contenido patrocinado